FHTX:NASDAQFoghorn Therapeutics Inc. Analysis

Foghorn Therapeutics (FHTX) trades around $4.14, just above its 20‑day SMA but still below the 50‑day and 200‑day averages, confirming a bearish price trend despite a modestly bullish MACD histogram. The stock sits near the identified support level of $3.54 and faces resistance around $4.59, while the 30‑day volatility exceeds 60% and beta is above 2, indicating pronounced price swings. Fundamentals are weak: revenue has collapsed by roughly 45%, margins are deeply negative, and cash flow remains negative despite a sizable cash pile of $184 M. Nonetheless, the company’s Gene Traffic Control platform is gaining visibility, with recent pre‑clinical data on its SMARCA2 inhibitor and degrader programs presented at major oncology conferences, and a strategic partnership with Eli Lilly on FHD‑909. Analyst price targets (median $12) imply more than 150% upside, but the lack of earnings, negative book value, and high risk profile temper optimism.